131 249

Cited 10 times in

Immunophenotypic Characterization and Quantification of Neoplastic Bone Marrow Plasma Cells by Multiparametric Flow Cytometry and Its Clinical Significance in Korean Myeloma Patients

Authors
 Young-Uk Cho  ;  Chan-Jeoung Park  ;  Seo-Jin Park  ;  Hyun-Sook Chi  ;  Seongsoo Jang  ;  Sang Hyuk Park  ;  Eul-Ju Seo  ;  Dok Hyun Yoon  ;  Jung-Hee Lee  ;  Cheolwon Suh 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.28(4) : 542-549, 2013 
Journal Title
JOURNAL OF KOREAN MEDICAL SCIENCE
ISSN
 1011-8934 
Issue Date
2013
MeSH
Adult ; Aged ; Aged, 80 and over ; Asian Continental Ancestry Group ; Bone Marrow Cells/cytology* ; Bone Marrow Cells/metabolism ; CD56 Antigen/metabolism ; Female ; Flow Cytometry ; Humans ; Immunophenotyping* ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/metabolism ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology* ; Neoplasm Staging ; Neoplastic Stem Cells/cytology* ; Neoplastic Stem Cells/metabolism ; Prognosis ; Republic of Korea ; Risk Factors ; Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism
Keywords
Flow Cytometry ; Immunophenotyping ; Multiple Myeloma ; Neoplastic Cells ; Plasma Cells
Abstract
Multiparametric flow cytometry (MFC) allows discrimination between normal and neoplastic plasma cells (NeoPCs) within the bone marrow plasma cell (BMPC) compartment. This study sought to characterize immunophenotypes and quantitate the proportion of NeoPCs in BMPCs to diagnose plasma cell myeoma (PCM) and evaluate the prognostic impact of this method. We analyzed the MFC data of the bone marrow aspirates of 76 patients with PCM and 33 patients with reactive plasmacytosis. MFC analysis was performed using three combinations: CD38/CD138/-/CD45; CD56/CD20/CD138/CD19; and CD27/CD28/CD138/CD117. The plasma cells of patients with reactive plasmacytosis demonstrated normal immunophenotypic patterns. Aberrant marker expression was observed in NeoPCs, with negative CD19 expression observed in 100% of cases, CD56+ in 73.7%, CD117+ in 15.2%, CD27- in 10.5%, CD20+ in 9.2%, and CD28+ in 1.3%. In PCM patients, more than 20% of NeoPCs/BMPCs were significantly associated with factors suggestive of poor clinical outcomes. Patients who were CD27- or CD56+/CD27-, demonstrated shorter overall survival than patients of other CD56/CD27 combinations. Our results support the clinical value of immunophenotyping and quantifying NeoPCs in PCM patients. This strategy could help to reveal poor prognostic categories and delineate surrogate markers for risk stratification in PCM patients.
Files in This Item:
T201302544.pdf Download
DOI
10.3346/jkms.2013.28.4.542
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Park, Seo Jin(박서진)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/87438
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links